Holen Sie sich die Stockscreener-App
199.33
0.86%
-1.73
Handel nachbörslich:
199.33
Schlusskurs vom Vortag:
$201.06
Offen:
$202
24-Stunden-Volumen:
658.35K
Relative Volume:
0.69
Marktkapitalisierung:
$12.27B
Einnahmen:
$4.27B
Nettoeinkommen (Verlust:
$-356.15M
KGV:
-33.39
EPS:
-5.9702
Netto-Cashflow:
$1.19B
1W Leistung:
+1.74%
1M Leistung:
+11.64%
6M Leistung:
+46.78%
1J Leistung:
+93.69%
1-Tages-Spanne:
$198.94
$202.57
1-Wochen-Bereich:
$192.32
$202.57
52-Wochen-Spanne:
$97.50
$202.57
Jazz Pharmaceuticals Plc Stock (JAZZ) Company Profile
Firmenname
Jazz Pharmaceuticals Plc
Sektor
Branche
Telefon
353-1-634-7800
Adresse
FIFTH FLOOR, WATERLOO EXCHANGE, DUBLIN
Compare JAZZ vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
JAZZ
Jazz Pharmaceuticals Plc
|
199.33 | 12.38B | 4.27B | -356.15M | 1.19B | -5.9702 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Jazz Pharmaceuticals Plc Stock (JAZZ) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-10 | Fortgesetzt | Raymond James | Outperform |
| 2026-02-27 | Eingeleitet | Barclays | Overweight |
| 2025-11-24 | Herabstufung | UBS | Buy → Neutral |
| 2025-07-15 | Eingeleitet | Deutsche Bank | Buy |
| 2025-03-07 | Hochstufung | UBS | Neutral → Buy |
| 2025-02-26 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2025-02-13 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-12-12 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-06-05 | Eingeleitet | Goldman | Buy |
| 2024-01-03 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-11-27 | Herabstufung | UBS | Buy → Neutral |
| 2023-09-29 | Eingeleitet | Raymond James | Mkt Perform |
| 2023-06-12 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2022-12-09 | Hochstufung | Goldman | Neutral → Buy |
| 2022-06-14 | Eingeleitet | UBS | Buy |
| 2022-04-06 | Herabstufung | Goldman | Buy → Neutral |
| 2021-11-19 | Fortgesetzt | Goldman | Buy |
| 2021-10-07 | Fortgesetzt | Jefferies | Buy |
| 2021-10-05 | Eingeleitet | Citigroup | Buy |
| 2021-09-23 | Eingeleitet | Needham | Buy |
| 2021-05-19 | Fortgesetzt | JP Morgan | Overweight |
| 2021-04-07 | Fortgesetzt | RBC Capital Mkts | Outperform |
| 2021-02-05 | Bestätigt | H.C. Wainwright | Buy |
| 2021-02-03 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2021-01-29 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-16 | Eingeleitet | UBS | Buy |
| 2020-11-03 | Bestätigt | H.C. Wainwright | Buy |
| 2020-10-09 | Bestätigt | H.C. Wainwright | Buy |
| 2020-09-14 | Herabstufung | Goldman | Neutral → Sell |
| 2020-09-14 | Fortgesetzt | JP Morgan | Overweight |
| 2020-08-06 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-07-28 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2020-07-23 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2020-04-06 | Eingeleitet | Jefferies | Buy |
| 2020-03-12 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2020-01-08 | Eingeleitet | Goldman | Neutral |
| 2019-08-21 | Herabstufung | Piper Jaffray | Overweight → Neutral |
| 2019-06-11 | Eingeleitet | Barclays | Overweight |
| 2019-03-20 | Eingeleitet | SunTrust | Buy |
| 2018-12-14 | Eingeleitet | Wolfe Research | Peer Perform |
| 2018-11-08 | Bestätigt | B. Riley FBR | Buy |
| 2018-08-08 | Bestätigt | Stifel | Buy |
| 2018-07-11 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2018-03-23 | Bestätigt | H.C. Wainwright | Neutral |
| 2018-03-19 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
Alle ansehen
Jazz Pharmaceuticals Plc Aktie (JAZZ) Neueste Nachrichten
Jazz Pharmaceuticals to Present Xywav Narcolepsy Data at 2026 AAN Annual Meeting - Sleep Review
Jazz Pharmaceuticals enters exclusive licensing deal with Saniona - MSN
Whats the RSI of Jazz Pharmaceuticals plc stockMarket Trend Review & Weekly Watchlist for Consistent Profits - baoquankhu1.vn
Bond Watch: Will CNH Industrial NV outperform its industry peers2026 News Drivers & Precise Swing Trade Alerts - baoquankhu1.vn
Is It Too Late To Consider Jazz Pharmaceuticals (JAZZ) After A 93% One Year Rally? - simplywall.st
Why Jazz Pharmaceuticals Stock’s EPS is Set to 3x in 2026 - TIKR.com
Does New Epidiolex Behavioral Data at AAN 2026 Reframe Jazz Pharmaceuticals’ (JAZZ) Neuroscience Strategy? - simplywall.st
Is Jazz Pharmaceuticals plc exposed to political risk2026 Bull vs Bear & Low Volatility Stock Recommendations - baoquankhu1.vn
Jazz Pharmaceuticals PLC Stock Intrinsic Values - GuruFocus
Jazz Pharmaceuticals (JAZZ) Receives Outperform Rating with New Price Target - GuruFocus
Is Jazz Pharmaceuticals (JAZZ) one of the best cheap biotech stocks to buy now? - MSN
Jazz Pharmaceuticals stock hits all-time high at 198.01 USD By Investing.com - Investing.com Australia
Patterns Watch: Is Jazz Pharmaceuticals plc exposed to political riskMarket Rally & Capital Efficiency Focused Ideas - baoquankhu1.vn
Raymond James initiates Jazz Pharmaceuticals stock coverage with outperform rating - Investing.com UK
Jazz Pharmaceuticals stock hits all-time high at 198.01 USD - Investing.com
Asparaginase Market Key Companies AnalysisServier - openPR.com
Jazz Pharmaceuticals Presents Research at AAN Annual Meeting on Rare Neurological Disorders - Intellectia AI
Jazz Pharmaceuticals to Present Research on Epidiolex® (cannabidiol) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution at the 2026 American Academy of Neurology Annual Meeting - PR Newswire
Jazz Pharmaceuticals PLC Stock Warning Signs | BSP:J2AZ34 - GuruFocus
Who's Buying or Selling Jazz Pharmaceuticals PLC (BSP:J2AZ34) Stock Today? - GuruFocus
Jazz Pharmaceuticals PLC Stock Operating Data - GuruFocus
Jazz Pharmaceuticals PLC (BSP:J2AZ34) Stock Earnings Transcripts - GuruFocus
Jazz Pharmaceuticals PLC Stock Historical Valuations | BSP:J2AZ34 - GuruFocus
Jazz Pharmaceuticals PLC (BSP:J2AZ34) Competitors 2026 - GuruFocus
Jazz Pharmaceuticals PLC (BSP:J2AZ34) Stock Price & 30 Year Financial Data - GuruFocus
Jazz Pharmaceuticals PLC (BSP:J2AZ34) Stock Forecast, Price Targets and Analysts Predictions - GuruFocus
Jazz Pharmaceuticals PLC (BSP:J2AZ34) Dividend - GuruFocus
Jazz Pharmaceuticals PLC (BSP:J2AZ34) Stock News, Headlines & Updates - GuruFocus
Jazz Pharmaceuticals PLC (BSP:J2AZ34) Valuation: Modestly Overvalued - GuruFocus
Jazz Pharmaceuticals PLC (BSP:J2AZ34) DCF Valuation - GuruFocus
Jazz Pharmaceuticals PLC (BSP:J2AZ34) Stock HoldersInstitutional & Insider Ownership - GuruFocus
Jazz Pharmaceuticals PLC (BSP:J2AZ34) Stock Price, Trades & News - GuruFocus
Decliners Report: Is Jazz Pharmaceuticals plc subject to activist investor interest2026 Winners & Losers & Safe Entry Point Identification - baoquankhu1.vn
Jazz Pharmaceuticals PLC R (J7Z.HM) Q2 FY2025 earnings call transcript - Yahoo Finance
Eosinophilic Esophagitis Market: Rapid Increment Driven by Innovation by 2034 – DelveInsight | Regeneron Pharma, Sanofi, Bristol-Myers Squibb, Ellodi Pharma, AstraZeneca, Allakos, EsoCap, Pfizer - Barchart.com
Epilepsy Pipeline 2026: Latest FDA Approvals, Clinical Trials, and Emerging Therapies Assessment by DelveInsight | Aquestive Therapeutics, Atnahs Pharma (Pharmanovia), Jazz Pharma, SK Biopharma - Barchart.com
Jazz projects $4.25B–$4.50B 2026 revenue while advancing rare disease and oncology launches - MSN
Autistic Disorder Pipeline 2026: Therapies Under Investigation, Clinical Trials Milestones, and FDA Approvals by DelveInsight | Jazz Pharma, Axial Therapeutics, Eli Lilly and Company, Scioto Bioscienc - Barchart.com
Jazz Pharmaceuticals plc (JAZZ) reports $1.2 billion Q4 revenue, beats $1.17B estimate - MSN
Rate Cut: Whats the RSI of Jazz Pharmaceuticals plc stockWeekly Stock Report & Stepwise Swing Trade Plans - baoquankhu1.vn
Capricorn Fund Managers Ltd Purchases New Shares in Jazz Pharmaceuticals PLC $JAZZ - MarketBeat
Why is Jazz (JAZZ) down 3.9% since last earnings report? - MSN
Jazz Pharmaceuticals PLC (J7Z.HM) Analyst insights, Price targets and Recommendations - Yahoo Finance Singapore
JAZZ Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Perpetual Ltd Lowers Stake in Jazz Pharmaceuticals PLC $JAZZ - MarketBeat
Jazz Pharmaceuticals PLC (J7Z.HM) stock major holders - Yahoo Finance Singapore
Jazz Pharmaceuticals PLC (J7Z.HM) stock price, news, quote and history - Yahoo Finance Singapore
Insider Sell: Bruce Cozadd Sells 6,000 Shares of Jazz Pharmaceuticals PLC (JAZZ) - GuruFocus
Jazz Pharmaceuticals plc (JAZZ) stock price, news, quote and history - uk.finance.yahoo.com
Insider Selling: Jazz Pharmaceuticals (NASDAQ:JAZZ) Director Sells 6,000 Shares of Stock - MarketBeat
Director at Jazz Pharmaceuticals (JAZZ) sells 6,000 company shares - Stock Titan
Finanzdaten der Jazz Pharmaceuticals Plc-Aktie (JAZZ)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.69%
0.25%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):